Found 6117 clinical trials
Care Partner Assisted Intervention to Improve Oral Health of Individuals With Mild Dementia
and quality of life for an extended period of time.
- 0 views
- 02 May, 2023
- 2 locations
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)
Primary Objective: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) Secondary Objectives: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population with allergic fungal rhinosinusitis (AFRS) at Week 24 To assess the …
- 123 views
- 19 May, 2023
- 5 locations
Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
- 19 views
- 15 Dec, 2022
- 75 locations
Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
therapy of ICS/LABA will be withdrawn during the 12week randomized treatment period and resumed at the end of the IMP treatment period, as outlined below: Screening period (4 weeks)
- 62 views
- 12 May, 2023
- 23 locations
A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into the Cerebrospinal Fluid of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)
weeks, or a little over 2 years. This includes the screening and follow-up periods. Participants will be given BIIB080 or placebo once every 12 weeks for a total of 72 weeks.
- 0 views
- 20 Apr, 2023
- 20 locations
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (EVEREST)
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving CRSwNP symptoms at Week 24 compared to omalizumab To evaluate the efficacy of dupilumab in improving lung function at …
- 92 views
- 12 May, 2023
- 76 locations
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. …
- 34 views
- 07 Apr, 2023
- 6 locations
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)
Primary Objective: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD Secondary Objectives: Primary population (former smokers cohort): Evaluate the efficacy of itepekimab compared with placebo on pulmonary function in former …
- 1102 views
- 06 Jun, 2023
- 111 locations
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety …
- 124 views
- 18 Apr, 2023
- 11 locations
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
The goal is to determine the efficacy, safety and tolerability for 300 patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)), or a placebo regimen for 52 weeks.Participants who complete all study visits may …
- 16 views
- 19 Dec, 2022
- 85 locations